Sorin Ioan BeșChea Chiriac
Research Subjects
Sorin Ioan BeșChea Chiriac has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra-Andreea CherșUnaru
Faculty of Veterinary Medicine, Ion Ionescu de la Brad Iasi University of Life Science, 700489 Iasi, Romania
1 shared publication - Alina Anton
Internal Medicine Unit, Clinics Department, Faculty of Veterinary Medicine, Iasi University of Life Sciences, Ion Ionescu de la Brad, 700490 Iasi, Romania
1 shared publication - Eugenia Dumitrescu
Department of Pharmacology and Pharmacy, University of Life Sciences “King Mihai I” from Timișoara, Calea Aradului 119, 300645 Timișoara, Romania
1 shared publication - Florin Nechifor
Reproduction, Clinics Department, Faculty of Veterinary Medicine, "Ion Ionescu de la Brad" Iasi University of Life Sciences, 8, Mihail Sadoveanu Alley, 700489, Iasi, Romania
1 shared publication Ioana Ștefania Cucoș
1 shared publication- Iulia Straton1 shared publication
Latest Publications
- 30 September 2026
- Published by Universitatea de Stiintele Vietii Regele Mihai I din Timisoara in Romanian Journal of Veterinary Sciences
- Vol. 59 (3) , 541-557
Sodium-glucose cotransporter 2 inhibitors versus insulin therapy in companion animals with diabetes mellitus: a systematic review of current evidence and therapeutic perspectives
Diabetes mellitus in companion animals represents a complex endocrine disorder with increasing prevalence, particularly in dogs and cats, requiring individualized and species-specific therapeutic approaches. This systematic review was conducted in accordance with the PRISMA 2020 Statement and compares two major therapeutic strategies—insulin therapy and sodium–glucose cotransporter 2 (SGLT2) inhibitors—while also analyzing factors influencing treatment selection, safety profiles, and emerging therapeutic perspectives. Insulin remains the cornerstone of diabetes management in both dogs and cats, providing reliable glycemic control across all disease stages, although its use is limited by the risk of hypoglycemia and the need for injectable administration and continuous monitoring. In contrast, SGLT2 inhibitors offer a novel oral, insulin-independent approach that improves owner compliance and demonstrates promising efficacy in selected stable feline patients, but their use is restricted by the risk of euglycemic ketoacidosis and limited applicability in insulin-dependent diabetes. Therapeutic decision-making is influenced by multiple factors, including species differences, disease pathophysiology, comorbidities, hepatic function, clinical experience, and owner-related constraints. Emerging therapies such as stem cell therapy, gene therapy, GLP-1 analogs, and advanced insulin delivery systems highlight the evolving landscape of veterinary diabetology and the potential for more personalized and regenerative treatment strategies in the future.
- 30 September 2026
- Published by Universitatea de Stiintele Vietii Regele Mihai I din Timisoara in Romanian Journal of Veterinary Sciences
- Vol. 59 (3) , 541-557
Sodium-glucose cotransporter 2 inhibitors versus insulin therapy in companion animals with diabetes mellitus: a systematic review of current evidence and therapeutic perspectives
Diabetes mellitus in companion animals represents a complex endocrine disorder with increasing prevalence, particularly in dogs and cats, requiring individualized and species-specific therapeutic approaches. This systematic review was conducted in accordance with the PRISMA 2020 Statement and compares two major therapeutic strategies—insulin therapy and sodium–glucose cotransporter 2 (SGLT2) inhibitors—while also analyzing factors influencing treatment selection, safety profiles, and emerging therapeutic perspectives. Insulin remains the cornerstone of diabetes management in both dogs and cats, providing reliable glycemic control across all disease stages, although its use is limited by the risk of hypoglycemia and the need for injectable administration and continuous monitoring. In contrast, SGLT2 inhibitors offer a novel oral, insulin-independent approach that improves owner compliance and demonstrates promising efficacy in selected stable feline patients, but their use is restricted by the risk of euglycemic ketoacidosis and limited applicability in insulin-dependent diabetes. Therapeutic decision-making is influenced by multiple factors, including species differences, disease pathophysiology, comorbidities, hepatic function, clinical experience, and owner-related constraints. Emerging therapies such as stem cell therapy, gene therapy, GLP-1 analogs, and advanced insulin delivery systems highlight the evolving landscape of veterinary diabetology and the potential for more personalized and regenerative treatment strategies in the future.